Emerging small-molecule treatments for multiple sclerosis: focus on B cells. (2019)
Attributed to:
Biomedical Catalyst – Drug product production, clinical support studies, and phase 1 trial of a new MS drug
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.12688/f1000research.16495.1
PubMed Identifier: 30863536
Publication URI: http://europepmc.org/abstract/MED/30863536
Type: Journal Article/Review
Volume: 8
Parent Publication: F1000Research
ISSN: 2046-1402